KAS
XLRN

Kestra Advisory Services’s Acceleron Pharma XLRN Stock Holding History

Kestra Advisory Services’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,654
Closed -$2.18M – 2244
2021
Q3 		$2.18M Sell
12,654
-118
-0.9% -$15.4K 0.02% 670
2021
Q2 		$1.6M Buy
12,772
+9
+0.1% +$1.14K 0.02% 737
2021
Q1 		$1.73M Sell
12,763
-231
-2% -$29.8K 0.02% 648
2020
Q4 		$1.66M Buy
12,994
+200
+2% +$23.5K 0.02% 658
2020
Q3 		$1.44M Buy
+12,794
New +$1.27M 0.03% 517

Kestra Advisory Services's XLRN Position: Q4 2021 in Review

Kestra Advisory Services sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 12,654 shares — an estimated $2.18M sold.

Kestra Advisory Services first reported a position in XLRN in Q3 2020 and held it in 5 quarters. The position peaked at $2.18M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Kestra Advisory Services reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 12,654 Acceleron Pharma shares in Q4 2021, an estimated $2.18M.
  • Kestra Advisory Services first reported a position in Acceleron Pharma in Q3 2020 and held it in 5 quarters.
  • Kestra Advisory Services's Acceleron Pharma position peaked at $2.18M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Kestra Advisory Services's 13F filing for Q4 2021, filed 20 Jan 2022.